CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PharmaTimes
High ImpactOriginal article

IMAVVY approved as first targeted therapy for wAIHA

RegulatoryapprovedIMAVVYPositive
AI Analysis

Summary

IMAVVY has been approved as the first targeted therapy for wAIHA, with a mechanism that reduces pathogenic IgG while preserving B-cell function.

Outcome Details

First targeted therapy approved for wAIHA

Importance:9/10
Sentiment:
0.90
FDA approvalfirst-in-classautoimmune diseaseimmunology
Related Companies

Read the original article

Published by PharmaTimes on September 1, 2026 10:15 AM

Read Original